Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8.
OBJECTIVE
Luteal phase physiology is distorted by in vitro fertilization (IVF) cycles using gonadotropin-releasing hormone (GnRH) agonists and antagonists, Controlled ovarian hyperstimulation leads to luteal phase defect and for this reason, luteal phase support is now an integral part of IVF/ICSI-ET programs. The support is provided by hCG, progesterone or GnRH-a. This study compared the efficiency, safety and tolerance of two vaginal micronized progesterones, Utrogestan and Crinone 8%.


METHODS
111 women, 18-40 years old, FSH < 10 IU/L and normal uterus findings were included. The efficiency of the two preparations to provide luteal support was evaluated by the fertilization, implantation, pregnancy and take-home baby rates. The safety was compared through the results of vaginal findings and vaginal inflammation markers before and after treatment. Comparison of tolerance was made by evaluating 21 subjective patient questionnaire parameters.


RESULTS
There were no significant differences between the preparations in terms of efficiency or safety though Crinone 8% was better tolerated.


CONCLUSIONS
The outcomes of this study suggest that a vaginal gel with micronized progesterone (Crinone 8%) is the optimal choice at this time for luteal support.
IVF Clinic Olomouc, Horni Lan 6, Olomouc, Czech Republic.
Lucie
L
Michnova
Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.
Jiri
J
Dostal
Department of Obstetrics and Gynecology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic.|Department of Health Care Sciences, Faculty of Humanities, Thomas Bata University in Zlin, Czech Republic.
Milan
M
Kudela
Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Petr
P
Hamal
Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic.
Katerina
K
Langova
D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D015925:Cryopreservation; D004334:Drug Administration Schedule; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D008183:Luteal Phase / Q000187:drug effects*; D010062:Ovulation Induction / Q000379:methods; D011247:Pregnancy; D011256:Pregnancy Outcome; D018873:Pregnancy Rate; D011374:Progesterone / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D011446:Prospective Studies; D014622:Vaginal Creams, Foams, and Jellies; D055815:Young Adult
C400424:Crinone; C000624167:Utrogestan; D014622:Vaginal Creams, Foams, and Jellies; D011374:Progesterone; D005640:Follicle Stimulating Hormone
Crinone 8%; IVF/ET; Progesterone; Utrogestan; luteal phase support